P/E ratio for Telix Pharmaceuticals (TLX.AX)
P/E ratio at the end of 2022: -21.1
According to Telix Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -45.1407. At the end of 2022 the company had a P/E ratio of -21.1.
P/E ratio history for Telix Pharmaceuticals from 2017 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -21.1 | -13.42% |
| 2021 | -24.3 | 27.69% |
| 2020 | -19.0 | 54.16% |
| 2019 | -12.4 | 38.34% |
| 2018 | -8.93 | -15.46% |
| 2017 | -10.6 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.